ArticleAmerican economic journal. Economic policy2018
Strategic Formulary Design in Medicare Part D Plans.
Article in American economic journal. Economic policy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 54 citations in OpenAlex.
- Impact of a real-time prescription benefit on adherence and utilization of low-cost prescription alternatives for members new to diabetes treatment.Journal of managed care & specialty pharmacy · 2025Article
- Medicare Part D insulin coverage: formulary strategies amid policy headwinds.Health affairs scholar · 2025Article
- Veterans Health Administration benefit value has little effect on reliance.The American journal of managed care · 2025Article
- Market segmentation by profit status: evidence from hospice.Health affairs scholar · 2024Article
- Medicare Part D Protected-Class Policy Is Associated With Lower Drug Rebates.Health affairs (Project Hope) · 2024Article
- Adverse selection and network design under regulated plan prices: Evidence from Medicaid.Journal of health economics · 2024Article
- Risk adjustment for regional healthcare funding allocations with ensemble methods: an empirical study and interpretation.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- A framework for ex-ante evaluation of the potential effects of risk equalization and risk sharing in health insurance markets with regulated competition.Health economics review · 2024Review
- Scope and Incentives for Risk Selection in Health Insurance Markets With Regulated Competition: A Conceptual Framework and International Comparison.Medical care research and review : MCRR · 2024Review
- The Two-Margin Problem in Insurance Markets.The review of economics and statistics · 2023Article
- How to deal with persistently low/high spenders in health plan payment systems?Health economics · 2022Article
- Variation in generic dispensing rates in Medicare Part D.The American journal of managed care · 2020Observational
- Effect of Carving in Pharmacy Benefits on Utilization and Costs.Journal of managed care & specialty pharmacy · 2020Article
- Incorporating self-reported health measures in risk equalization through constrained regression.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- Data transformations to improve the performance of health plan payment methods.Journal of health economics · 2019Article
- Screening in Contract Design: Evidence from the ACA Health Insurance Exchanges.American economic journal. Economic policy · 2019Article
- Adjusted Mortality Rates Are Lower For Medicare Advantage Than Traditional Medicare, But The Rates Converge Over Time.Health affairs (Project Hope) · 2019Article
- Getting What We Pay For: How Do Risk-Based Payments to Medicare Advantage Plans Compare with Alternative Measures of Beneficiary Health Risk?Health services research · 2018Article
- Private provision of social insurance: drug-specific price elasticities and cost sharing in Medicare Part D.American economic journal. Economic policy · 2018Article
- Measuring efficiency of health plan payment systems in managed competition health insurance markets.Journal of health economics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The design of Medicare Part D causes most beneficiaries to receive fragmented health insurance, with drug and medical coverage separated. Fragmentation is potentially inefficient since separate insurers optimize over only one component of healthcare spending, despite complementarities and substitutabilities between healthcare types. Fragmentation of only some plans can also lead to market distortions due to differential adverse selection, as integrated plans may use drug formularies to induce enrollment by patients that are profitable in the medical insurance market. We study the design of insurance plans in Medicare Part D, and find that formularies reflects these two differences in incentives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.